Last reviewed · How we verify
Infection of biliary tract — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Ancef In Sodium Chloride 0.9% In Plastic Container | CEFAZOLIN | GSK | Cephalosporin Antibacterial | 1973-01-01 | ||
| Ancef In Sodium Chloride 0.9% In Plastic Container | Cefazolin Sodium | GSK | Cephalosporin | Bacterial cell wall peptidoglycan | 1973-01-01 | |
| Cefazoline | Cefazoline | Nantes University Hospital | Bacterial penicillin-binding protein, Penicillin-binding protein 1A | |||
| Cephazolin | Cephazolin | HaEmek Medical Center, Israel | Bacterial penicillin-binding protein, Penicillin-binding protein 1A |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- GSK · 2 drugs in Infection of biliary tract
- HaEmek Medical Center, Israel · 1 drug in Infection of biliary tract
- Nantes University Hospital · 1 drug in Infection of biliary tract
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Infection of biliary tract:
- Infection of biliary tract treatment updates — RSS
- Infection of biliary tract treatment updates — Atom
- Infection of biliary tract treatment updates — JSON
Cite this brief
Drug Landscape (2026). Infection of biliary tract — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-of-biliary-tract. Accessed 2026-06-10.
Related
- Infection of biliary tract full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing